Johnson Fistel Investigates Soleno Therapeutics
Johnson Fistel, a prominent law firm representing shareholder rights, has initiated an investigation regarding Soleno Therapeutics, Inc. (NASDAQ: SLNO). This inquiry focuses on whether the company, alongside some of its executives, may have violated federal securities laws. Allegations suggest that misleading statements and omissions could have harmed investors.
Understanding the Investigation
The investigation looks deeper into the communications that Soleno has had with its public investors, especially regarding the commercial success and safety profile of its recently approved product, VYKAT™ XR.
VYKAT™ XR’s Approval and Market Response
In September 2025, Soleno announced that VYKAT™ XR received clearance from the FDA, indicating a positive outlook on the product's market entry. The company promoted that its rollout was exceeding expectations, a significant narrative for stakeholders.
Challenges Following Product Launch
However, during a recently held earnings call on November 4, 2025, the management brought to light several challenges encountered since the product's launch. They noted a noticeable slowdown in new treatment starts and a concerning increase in therapy discontinuations, attributed to non-serious adverse events. This downward trend has raised eyebrows and cast doubt on earlier optimistic statements.
The Impact of External Reports
A report released on August 15, 2025, by Scorpion Capital suggested serious concerns about VYKAT™ XR and the overall commercialization strategy of Soleno. The report critiqued the safety of the drug, questioned the strength of its demand, and pointed out over-reliance on a singular product, with critical patent protections nearing expiration.
Stock Price Fluctuations
After the negative commentary from the short seller, Soleno’s stock faced severe volatility. Between mid-August and early November, SLNO shares saw a staggering drop of close to 40%. Such fluctuations have understandably distressed shareholders.
Investors Encouraged to Join Investigation
If you have purchased SLNO shares and believe that your investment has been adversely affected, you are encouraged to participate in this investigation. This could provide a pathway for recourse for affected shareholders.
About Johnson Fistel, PLLP
Johnson Fistel is known for its commitment to protecting shareholder rights. With offices spread across various states, this law firm is experienced in handling shareholder derivative and securities class action lawsuits effectively. It even provides services for foreign investors who engaged in U.S. markets.
Achievements of Johnson Fistel
In 2024, Johnson Fistel was recognized among the Top 10 Plaintiff Law Firms in the nation, reflecting its successful recovery of significant funds for investors. The firm has earned this distinction multiple times in the past, demonstrating its expertise.
Contacting Johnson Fistel
For further inquiries or to learn more about the ongoing investigation, interested individuals can reach out to the firm. They can contact Jim Baker or Frank J. Johnson at (619) 814-4471. There is no financial obligation for potential clients seeking guidance.
Frequently Asked Questions
What is the purpose of Johnson Fistel's investigation?
The investigation aims to determine if Soleno Therapeutics misled investors regarding its products and safety while possibly violating securities laws.
What concerns were raised about VYKAT™ XR?
Concerns were expressed about the product's safety profile, demand sustainability, and reliance on a single product amid an early warning about its commercialization.
What impact did the Scorpion Capital report have?
The report brought serious allegations leading to a significant stock price drop of nearly 40% for SLNO shares after its release.
How can affected shareholders get involved?
Affected shareholders can join the ongoing investigation by contacting Johnson Fistel for more information.
What does Johnson Fistel specialize in?
The firm specializes in securities fraud cases and shareholder rights law, representing both individual and institutional investors effectively.
